Viral Technology Laboratory

病毒技术实验室

• 批准号: 7578021
• 金额: $ 92.57万
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7578021
• 关键词: Viral; Technology; Laboratory

The Viral Technology Laboratory (VTL) at the National Cancer Institute - Frederick focuses on oncogenic viral pathogenesis and the role of viruses in cancer etiology. Using a combination of well-established techniques as well as cutting-edge technologies, VTL performs virological assays that are sensitive, specific, cost-effective, and time-efficient. VTL also produces custom lentiviruses and adenoviruses for transgene or shRNA delivery. These viruses are powerful tools that enable researchers to manipulate and study the role of specific genes in the etiology of cancer and various other disease states. VTL offers cDNA cloning for gene expression, as well as design, generation, and purification of recombinant lentiviruses and adenoviruses for gene delivery and expression studies in vitro and in vivo. VTL also performs molecular and serological laboratory testing on a variety of specimen types (blood, cells, buffy coat, saliva, tissues, tumors, etc.) to detect and characterize viruses that cause human cancers. During the past year, this laboratory has undergone several major changes. It was previously the Viral Oncology Section (VOS) of the AIDS Vaccine Program (AVP), but on October 1, 2006, the laboratory transferred to the Advanced Technology Program (ATP). As of April 1, 2007, the Gene Expression Laboratory (GEL) was disbanded and the GEL Virus Production Group merged with the VOS core laboratory. This added two full-time employees, as well as the lentiviral and adenoviral services, and as a result, VOS core was renamed the Viral Technology Laboratory (VTL).VTL collaborates with NCI investigators to determine and provide the most scientifically sound and costeffective solution for the requested virological service. VTL consists of two groups: the Serology and Molecular Assays Group and the Virus Production Group that together offer an extensive catalog of virology services to help investigators move their research forward. SEROLOGY AND MOLECULAR ASSAYS GROUP This VTL group offers luminex multiplex cytokine and cell signaling assays; antibody detection and quantification using in-house and commercial ELISAs; validated quantitative real-time PCR viral testing (standardized to International Units); automated highthroughput DNA and RNA extraction of viral and mammalian nucleic acids for various downstream uses, including PCR and SNP analysis; DNA sequencing; development of custom expression arrays for whole virus genomes or cellular pathways; and sample testing using these arrays as well as AFFYMETRIX human gene arrays. VTL was originally established in 1986 as the Viral Epidemiology Section (VES) to support large-scale, population-based epidemiological studies performed by investigators of the NCI Division of Cancer Epidemiology and Genetics (NCI-DCEG) Viral Epidemiology Branch (VEB).

国家癌症研究所的病毒技术实验室（VTL） - 弗雷德里克（Frederick）着重于致癌病毒发病机理和病毒在癌症病因中的作用。 VTL结合了建立良好的技术以及尖端的技术，进行了敏感，特定，具有成本效益且效率的病毒学测定法。 VTL还产生定制的慢病毒和腺病毒，用于转基因或shRNA递送。这些病毒是强大的工具，使研究人员能够操纵和研究特定基因在癌症和其他疾病状态的病因中的作用。 VTL提供了用于基因表达的cDNA克隆，以及重组慢病毒和腺病毒的设计，生成和纯化，用于基因递送和体外和体内的基因递送和表达研究。 VTL还对各种样品类型（血液，细胞，浅面涂层，唾液，组织，肿瘤等）进行分子和血清学实验室测试，以检测和表征引起人类癌症的病毒。在过去的一年中，该实验室经历了几次重大变化。它以前是艾滋病疫苗计划（AVP）的病毒肿瘤科（VOS），但在2006年10月1日，实验室转移到了先进技术计划（ATP）。截至2007年4月1日，基因表达实验室（GEL）被解散，凝胶病毒生产组与VOS核心实验室合并。这增加了两名全职员工以及慢病毒和腺病毒服务，因此，VOS Core被更名为病毒技术实验室（VTL）.VTL与NCI研究人员合作，以确定并为请求的病毒学服务确定并为最科学的声音和成本效益。 VTL由两个小组组成：血清学和分子测定组和病毒生产小组，共同提供广泛的病毒学服务目录，以帮助研究人员推动他们的研究前进。 血清学和分子测定组 该VTL组提供Luminex多重细胞因子和细胞信号传导测定。使用内部和商业ELISA的抗体检测和定量；经过验证的定量实时PCR病毒测试（标准化为国际单位）；自动高通量DNA和病毒和哺乳动物核酸的RNA提取各种下游用途，包括PCR和SNP分析； DNA测序；开发整个病毒基因组或细胞途径的自定义表达阵列；并使用这些阵列以及Affymetrix人基因阵列进行样品测试。 VTL最初于1986年建立为病毒流行病学科（VES），以支持由NCI癌症流行病学和遗传学研究人员（NCI-DCEG）病毒流行病学分支（VEB）进行的大规模基于人群的流行病学研究。